Drug intelligence / Profile preview

OpKinib

Development stage: Preclinical
Lead developer: Pharma in Silica
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

OpKinib is a preclinical-stage therapeutic candidate being developed by Pharma in Silica for the treatment of solid cancers. It consists of a novel, in-licensed small molecule kinase inhibitor integrated into a proprietary controlled-release formulation, likely utilizing the company's silica nanoparticle delivery platform. By employing a controlled-release mechanism, OpKinib aims to improve the therapeutic window and efficacy of the kinase inhibitor payload. The specific kinase target has not been disclosed by the developer.

Brand names: OpKinib

Beyond the preview

Go deeper on OpKinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OpKinib.

Explore the full profile